FRCOphth Part 1 Comprehensive Study Notes

Optics and Refraction

• Electromagnetic Spectrum & Light Wavelengths:

  • The visible wavelength range of the electromagnetic spectrum spans $400\text{--}780\,nm$.
  • Fluorescein sodium absorbs light in the blue spectrum ($465\text{--}490\,nm$) and emits light in the yellow-green spectrum ($520\text{--}530\,nm$).
  • Indocyanine green (ICG) absorbs light at approximately $810\,nm$ and emits fluorescence in the near-infrared spectrum at approximately $830\,nm$.
  • Blue and green light scatter significantly more than red light because blue and green light possess shorter wavelengths; red light has a longer wavelength.
  • Wavelength is defined as the distance between two symmetrical parts of a wave motion (one complete cycle).
  • Amplitude represents the maximum displacement of an imaginary particle on the wave from the baseline.
  • Phase denotes any portion of a cycle.
  • Wavelengths between $400\,nm$ and $1400\,nm$ can penetrate the ocular media and reach the retina.

• Radiometry and Photometry Units:

  • Radiant intensity measures total radiant energy per unit solid angle and is expressed in watts per steradian ($W/sr$).
  • Luminous intensity measures visual light power per unit solid angle and is expressed in candelas ($cd$), which equals lumens per steradian ($lm/sr$).
  • Luminous energy is measured in joules ($J$) or lumen-seconds.
  • Photometric units and equivalences:
  • $1\,\text{apostilb} = 1\,\text{lumen/m}^2$
  • $1\,\text{lux} = 1\,\text{lumen/m}^2 = 1\,\text{metre-cancela}$
  • $1\,\text{lambert} = 1\,\text{candela}$ at $1\,cm$ distance for a perfectly diffusing light source on a surface at $1\,cm$
  • $1\,\text{troland}$ represents retinal illuminance produced by a surface luminance of $1\,\text{cd/m}^2$ viewed through a pupil area of $1\,\text{mm}^2$

• Reflection, Mirrors, and Image Formation:

  • Plane Mirrors: Rotating a plane mirror through an angle $0$ causes the reflected ray to deviate through an angle equal to $2\theta$. Images formed by plane mirrors are erect, virtual, and laterally inverted.
  • Concave Mirrors:
  • Object outside the Centre of Curvature ($C$): Formed image is Real, Inverted, and Diminished (RID).
  • Object between Centre of Curvature ($C$) and Principal Focus ($F$): Formed image is Real, Inverted, and Enlarged (RIE).
  • Object inside Principal Focus ($F$): Formed image is Virtual, Erect, and Enlarged (VEE).     
  • Convex Mirrors: For an object at any distance, the image formed is Virtual, Erect, and Diminished (VED).     

• Total Internal Reflection & Prisms:

  • Fiberoptic cables utilize total internal reflection to transmit light signals.
  • Prism Power & Deviation:
  • $1\,\text{prism dioptre}\ (\Delta)$ produces an apparent displacement of $1\,cm$ for an object situated at a distance of $1\,m$ ($100\,cm$).
  • An apparent deviation of $1\,\Delta$ is equivalent to an angle of deviation of approximately $\frac{1}{2}^\circ$ ($0.57^\circ$).
  • In the Prentice position, the angle of incidence does not equal the angle of emergence; the incident ray enters perpendicular to the first prism surface.
  • A Wollaston prism consists of two quartz prisms cemented together with mutually perpendicular optical axes; it splits an incident unpolarized light beam into two orthogonally polarized emerging beams, producing two sharp images.
  • Porro, Dove, and Right-angle prisms are utilized to invert or reverse optical images.

• Refractive Indices of Ocular Media and Optical Materials:

  • Air: $1.000$
  • Cornea: $1.376$
  • Tear film and Aqueous humor: $1.336$
  • Crystalline lens (cortex to core gradient): $1.386\text{--}1.406$
  • Vitreous humor: $1.336$
  • Crown glass: $1.520$

• Schematic and Reduced Eye Models:

  • Gullstrand's Schematic Eye: Total refractive power is $+58.64\,\text{dioptres}$.
  • First principal point ($P_1$): $1.35\,mm$ behind the anterior corneal surface.
  • Second principal point ($P_2$): $1.60\,mm$ behind the anterior corneal surface.
  • First nodal point ($N_1$): $7.08\,mm$ behind the anterior corneal surface.
  • Second nodal point ($N_2$): $7.33\,mm$ behind the anterior corneal surface.
  • First focal point ($F_1$): $-15.7\,mm$ in front of the anterior corneal surface.
  • Second focal point ($F_2$): $24.4\,mm$ behind the anterior corneal surface.     
  • Reduced Eye Model: Total refractive power is $+58.6\,\text{dioptres}$.
  • Principal point ($P$): $1.35\,mm$ behind the anterior corneal surface.
  • Nodal point ($N$): $7.08\,mm$ behind the anterior corneal surface.
  • First focal point ($F_1$): $-15.7\,mm$ in front of the anterior corneal surface.
  • Second focal point ($F_2$): $24.13\,mm$ behind the anterior corneal surface.     

• Purkinje-Sanson Images:

  • Image I: Reflected from the anterior corneal surface (Virtual, Erect).
  • Image II: Reflected from the posterior corneal surface (Virtual, Erect).
  • Image III: Reflected from the anterior lens surface (Virtual, Erect, largest).
  • Image IV: Reflected from the posterior lens surface (Real, Inverted, smallest). Images II, III, and IV are utilized in optical pachymetry and anterior segment evaluation.

• Spherical and Cylindrical Lenses, Transposition, and Astigmatism:

  • Simple Transposition Steps:
  1. Sum: Add the algebraic powers of the sphere and cylinder to determine the new sphere power.
  2. Sign: Change the sign of the cylinder power ($+\rightarrow -$ or $-\rightarrow +$).
  3. Axis: Rotate the cylindrical axis by $90^\circ$ (add $90^\circ$ if original axis is $\le 90^\circ$; subtract $90^\circ$ if original axis is $> 90^\circ$).
  • Spherical Equivalent Formula:$\text{Spherical Equivalent} = \text{Sphere Power} + \frac{1}{2}(\text{Cylinder Power})$
  • Jackson Cross Cylinder: A sphero-cylindrical lens in which the cylinder power is twice the power of the sphere and opposite in sign (e.g., $+0.25\,\text{DS} / -0.50\,\text{DC}$).
  • Classification of Astigmatism:
  • Simple Myopic Astigmatism: One focal line lies on the retina, while the second focal line lies in front of the retina.
  • Compound Myopic Astigmatism: Both focal lines lie in front of the retina.
  • Simple Hypermetropic Astigmatism: One focal line lies on the retina, while the second focal line lies behind the retina.
  • Compound Hypermetropic Astigmatism: Both focal lines lie behind the retina.
  • Mixed Astigmatism: One focal line lies in front of the retina, while the second focal line lies behind the retina.
  • Sturm's Conoid & Circle of Least Confusion: The focal point of the spherical equivalent coincides with the circle of least confusion (the region of minimal blur between the two principal focal lines). Toric lenses are expressed mathematically as a fraction with spherical power in the numerator and cylindrical power in the denominator.

• Accommodation, Presbyopia, and Hypermetropia:

  • Static Refraction: The dioptric power of the unaccommodated eye at rest.
  • Dynamic Refraction: The dioptric power of the accommodated eye.
  • Manifest Hypermetropia: The strongest convex lens accepted for clear distance visual acuity.
  • Latent Hypermetropia: Hypermetropia masked by ciliary muscle tone and involuntary accommodation.
  • Facultative Hypermetropia: Portion of hypermetropia that can be overcome by accommodation.
  • Absolute Hypermetropia: Portion of hypermetropia exceeding the total amplitude of accommodation.
  • Presbyopia: Comfortable near vision requires retaining at least $\frac{1}{3}$ of the total available accommodation amplitude in reserve.

• Aphakia Correction and Magnification:

  • The effective refractive power of the crystalline lens in situ is approximately $+15\,\text{D}$.
  • Correcting aphakia with spectacles requires a power of $+18\text{--}+20\,\text{D}$ at the spectacle plane due to vertex distance effectivity.
  • Spectacle correction of aphakia induces optical complications including ring scotoma, jack-in-the-box phenomenon, pin-cushion distortion, heavy lenses, and $\approx 20\text{--}30\%$ magnification (aniseikonia).
  • Pre-existing axial myopia of $-18\text{ to }-20\,\text{D}$ renders an aphakic eye emmetropic post-cataract extraction without an intraocular lens.
  • Loupe Magnification: Lens power in dioptres is calculated as $\text{Magnification} \times 4\,\text{D}$ (e.g., a $\times 8\,\text{loupe}$ possesses a lens power of $32\,\text{dioptres}$).
  • Hand and stand magnifiers: The field of view depends directly on the lens aperture size and the distance between the eye and the lens.

• Bifocals, Progressive Addition Lenses (PALs), and Spectacle Aberrations:

  • Prismatic Jump: Minimised when the optical centres of the distance and near portions lie at or near the junction line of the segments.
  • Progressive Addition Lenses (PALs):
  • Hard Design: Features wider distance and near visual fields, a narrower power progression corridor, and more rapid, steep peripheral unwanted astigmatism.
  • Soft Design: Features a wider power progression corridor, smaller distance/near zones, and lower peak peripheral astigmatism, yielding better tolerance.

• Clinical Optical Instruments:

  • Retinoscopy: Provides an objective measurement of ocular refraction. An image of the illuminated retina forms at the patient's far point. Stages include Illumination, Reflex, and Projection stages. Working distance deduction: $50\,cm = +2.00\,\text{D}$; $66\,cm = +1.50\,\text{D}$.
  • Javal-Schiøtz Keratometer: Employs a variable object size consisting of two illuminated mires (A and B) and a Wollaston prism for image doubling. Measures the curvature of the central $3\,mm$ anterior corneal surface along principal meridians.
  • Focimeter (Lensmeter): Measures major dioptric powers, principal cylindrical axes, and prismatic powers. Utilizes a green filter ($520\text{--}530\,nm$) to eliminate chromatic aberration.
  • Geneva Lens Measure: Calibrated specifically for lens materials made of crown glass (refractive index $1.520$).
  • Direct Ophthalmoscope: Produces a real, erect, magnified image ($\approx \times 15$). Field of view expands with pupil dilation, reduced viewing distance, or in hypermetropic eyes compared to myopic eyes.
  • Indirect Ophthalmoscope: Produces a real, aerial, vertically and horizontally inverted image. Magnification delivered: $+13\,\text{D}$ condensing lens yields $\approx \times 5$; $+20\,\text{D}$ condensing lens yields $\approx \times 3$
  • Slit Lamp Biomicroscope: Consists of a low-power binocular compound microscope ($\approx \times 10\text{--}\times 16$) integrated with a slit illumination system sharing a common focal point (isocentric). Filters include Cobalt blue ($465\text{--}490\,nm$) for fluorescein applanation and Green/red-free ($520\text{--}530\,nm$) for evaluating the vitreous, retinal nerve fiber layer, and vasculature.
  • Goldmann Applanation Tonometer: Based on the Imbert-Fick principle. An applanation contact area diameter of $3.06\,mm$ (area $7.35\,\text{mm}^2$) balances corneal rigidity against tear surface tension ($1\,g = 10\,mmHg$).     
  • Galilean Telescope: Formed by a convex objective lens and a concave eyepiece lens, producing an erect, magnified image by increasing the angle subtended by the object at the eye.
  • LASER Technology: Acronym for Light Amplification by Stimulated Emission of Radiation. Optical pumping elevates ground-state electrons into higher energy metastable states. Neodymium-doped yttrium aluminum garnet (Nd:YAG) lasers emit infrared radiation at $1064\,nm$ for photodisruption.

Ophthalmic Anatomy and Embryology

• Orbital Anatomy and Bony Boundaries:
  • Seven bones comprise the orbit: Maxilla, Frontal, Zygomatic, Ethmoid, Lacrimal, Sphenoid, and Palatine (Mnemonic: "Many Friendly Zebras Enjoy Lazy Summer Picnics").
  • Bony wall components:
  • Roof: Orbital plate of Frontal bone, Lesser wing of Sphenoid.
  • Floor: Orbital plate of Maxilla, Orbital surface of Zygomatic bone, Orbital process of Palatine bone.
  • Lateral Wall: Zygomatic bone, Greater wing of Sphenoid.
  • Medial Wall: Frontal process of Maxilla, Lacrimal bone, Orbital plate of Ethmoid (largest wall component), Body of Sphenoid (Mnemonic: "My Little Eye Sits in the orbit").
  • Skull Foramina and Transmitted Neural Structures:
  • Optic Canal: Optic nerve (CN II), Ophthalmic artery.
  • Superior Orbital Fissure (SOF):
    • Inside Common Tendinous Ring (Annulus of Zinn): Superior division of Oculomotor nerve (CN III), Inferior division of Oculomotor nerve (CN III), Nasociliary nerve ($\text{CN V}_1$), Abducens nerve (CN VI).
    • Outside Annulus of Zinn: Lacrimal nerve ($\text{CN V}_1$), Frontal nerve ($\text{CN V}_1$), Trochlear nerve (CN IV), Superior Ophthalmic vein, Inferior Ophthalmic vein (Mnemonic: "Live Frankly To See Absolutely No Insult").
  • Foramen Rotundum: Maxillary nerve ($\text{CN V}_2$).
  • Foramen Ovale: Mandibular nerve ($\text{CN V}_3$), Accessory meningeal artery, Lesser petrosal nerve.
  • Foramen Spinosum: Middle meningeal artery and vein, Meningeal branch of CN V_3$.\n * Foramen Lacerum: Perforates the apex of the petrous temporal bone.\n * Jugular Foramen: Glossopharyngeal nerve (CN IX), Vagus nerve (CN X), Accessory nerve (CN XI), Internal jugular vein.\n\n* **Eyelids, Eyebrows, and Ocular Adnexa:** conversion\n * Eyelid Dimensions: Margin thickness is approximately 2\,mm$; total margin length is approximately$30\,mm.\n * Eyelid Layers (Superficial to Deep):\n 1. Skin\n 2. Subcutaneous tissue\n 3. Striated muscle (Orbicularis oculi)\n 4. Orbital septum and Tarsal plates\n 5. Smooth muscle (Müller's muscle)\n 6. Palpebral Conjunctiva\n * Orbicularis Oculi: Supplied by Temporal and Zygomatic branches of the Facial nerve (CN VII). Palpebral portion operates voluntarily and involuntarily in front of the orbital septum; Lacrimal portion (Horner's muscle) draws eyelids medially and dilates the lacrimal sac.\n * Meibomian Glands: Modified sebaceous glands situated vertically within the tarsal plates (\approx 30 in the upper lid, slightly fewer in the lower lid).\n * Eyebrow Musculature: Frontalis muscle elevates the eyebrows; Orbital portion of Orbicularis oculi lowers eyebrows; Corrugator supercilii draws eyebrows medially (frowning).\n\n* **Extraocular Muscle Anatomy and Kinematics:**\n * Recti Muscle Insertions from Limbus (Spiral of Tillaux): Medial rectus (5.5\,mm$), Inferior rectus ($6.5\,mm$), Lateral rectus ($6.9\,mm$), Superior rectus ($7.7\,mm) (Mnemonic: MILS).\n * Tendon Lengths: Lateral rectus (8.8\,mm$, longest), Superior rectus ($5.8\,mm$), Inferior rectus ($5.5\,mm$), Medial rectus ($3.7\,mm).\n * Extraocular Muscle Innervation and Actions:\n * Superior Rectus (CN III superior division): Elevation (primary), Adduction (secondary), Intorsion (tertiary).\n * Inferior Rectus (CN III inferior division): Depression (primary), Adduction (secondary), Extorsion (tertiary).\n * Medial Rectus (CN III inferior division): Adduction (primary).\n * Lateral Rectus (CN VI): Abduction (primary).\n * Superior Oblique (CN IV): Intorsion (primary), Depression (secondary), Abduction (tertiary).\n * Inferior Oblique (CN III inferior division): Extorsion (primary), Elevation (secondary), Abduction (tertiary).\n * Extraocular Fiber Types:\n * Type A: Saccadic eye movements (fast-twitch).\n * Type B: Smooth pursuit eye movements.\n * Type C: Fine local tonic contractions.\n * Fick's Axes of Rotation:\n * Vertical Axis: Abduction and Adduction.\n * Transverse Axis: Elevation and Depression.\n * Sagittal Axis: Intorsion and Extorsion (Incycloduction and Excycloduction).\n\n* **Cornea, Sclera, and Anterior Chamber Angle:**\n * Cornea Dimensions: Horizontal diameter is 11.7\,mm$; Vertical diameter is$10.6\,mm$. Radius of curvature: Anterior surface =$7.7\,mm$; Posterior surface =$6.9\,mm$.
  • Layers of the Cornea (Anterior to Posterior):
  1. Epithelium ($50\text{--}60\,\mu m$ thick, 5-6 layers non-keratinized stratified squamous cells; complete cell turnover takes 7-10 days).
  2. Bowman's Layer (acellular collagenous matrix).
  3. Stroma ($\approx 90\%$ of total corneal thickness, orthogonal type I collagen lamellae).
  4. Pre-Descemet's Layer (Dua's Layer).
  5. Descemet's Membrane (basement membrane of corneal endothelium).
  6. Endothelium (single monolayer of non-regenerative hexagonal cells).
  • Sclera: Forms $\frac{5}{6}$ of the outer tunic of the eyeball. Pierced by the optic nerve at the lamina cribrosa ($3\,mm$ medial and $1\,mm$ superior to the posterior pole).
  • Anterior Chamber Angle Structures (Posterior to Anterior): Iris, Ciliary body, Scleral spur, Trabecular meshwork, Schwalbe's line (Mnemonic: "I Can't See This Stuff"). Total anterior chamber volume is approximately 0.2\,mL$.\n\n* **Uveal Tract (Iris, Ciliary Body, Choroid):**\n * Iris: Diameter is approximately 12\,mm$. Divided into pupillary and ciliary zones by the collarette. Stroma is derived from mesoderm; double posterior pigmented epithelium is derived from neuroectoderm. Sphincter pupillae ($1\,mm wide smooth muscle band, innervated by parasympathetic postganglionics via short ciliary nerves); Dilator pupillae (innervated by sympathetic fibers).\n * Ciliary Body: Total width is 6\,mm$($6.5\,mm$temporally,$5.5\,mm$nasally). Triangular in cross-section. Anterior pars plicata ($2\,mm$) contains ciliary processes; posterior pars plana ($4\,mm).\n * Choroid: Thickest at the posterior pole (\approx 0.22\,mm$), thinnest proximal to the optic disc ($\approx 0.1\,mm). Outer surface is roughened at the suprachoroidal space.\n\n* **Retina, Lens, and Vitreous:**\n * **Retinal Layers (Inner/Vitreous to Outer/Choroid):**\n 1. Internal Limiting Membrane (ILM)\n 2. Nerve Fiber Layer (NFL)\n 3. Ganglion Cell Layer (GCL)\n 4. Inner Plexiform Layer (IPL)\n 5. Inner Nuclear Layer (INL)\n 6. Outer Plexiform Layer (OPL) - divides inner retina (central retinal artery supply) from outer retina (choriocapillaris supply).\n 7. Outer Nuclear Layer (ONL)\n 8. External Limiting Membrane (ELM)\n 9. Ellipsoid Zone / Photoreceptor Layer\n 10. Retinal Pigment Epithelium (RPE)\n    (Mnemonic: "In New Generation, It Isn't Only Ophthalmologists Examining Every Retina").\n    \n * **Optic Nerve Segments and Lengths:**\n * Intraocular: 1\,mm\n * Intraorbital: 25\,mm\n * Intracanalicular: 5\,mm\n * Intracranial: 10\,mm\n * Total length is approximately 40\,mm$. Contains$\approx 1.2\,\text{million}$myelinated axons (90$6.5\,mm$at birth to$10\,mm$in adults. Capsule is thickest near the equator ($\approx 20\,\mu m$) and thinnest at the posterior pole ($\approx 3\,\mu m). Features an erect Y-suture anteriorly and an inverted Y-suture posteriorly.\n * **Vitreous Body:** Occupies \frac{4}{5}$($80\%$) of total ocular volume ($\approx 4\,mL).\n\n* **Visual Pathway and Neuroanatomy:**\n * Lateral Geniculate Nucleus (LGN): 6 layered nucleus located on the undersurface of the pulvinar of the thalamus.\n * Layers 1, 4, 6: Receive crossed input from contralateral optic axons.\n * Layers 2, 3, 5: Receive uncrossed input from ipsilateral optic axons.\n * Layers 1 and 2 = Magnocellular layers; Layers 3 to 6 = Parvocellular layers.\n * Cavernous Sinus: Lateral wall contains CN III, CN IV, CN V_1$, CN$V_2 (superior to inferior). Internal carotid artery and CN VI travel through the body of the sinus.\n\n* **Ocular Embryology Timeline:**\n * Day 27: Lens placode identified.\n * Day 36: Lens vesicle completely separates from surface ectoderm.\n * Week 5: Extraocular muscles identified (Lateral rectus, Superior rectus, Levator palpebrae superioris).\n * Week 6: Secondary vitreous appears; Superior oblique and Medial rectus appear.\n * Week 8: End of embryonic period, eyeball diameter reaches 1.5\text{--}2.0\,mm$.
  • Embryological Origins:
  • Surface Ectoderm: Corneal epithelium, conjunctival epithelium, crystalline lens, lacrimal glands, tarsal glands.
  • Neural Ectoderm: Neural retina, RPE, optic nerve fibers, iris epithelia, pupillary sphincter and dilator muscles, ciliary epithelium.
  • Mesoderm / Neural Crest: Corneal stroma, corneal endothelium, sclera, iris stroma, ciliary muscle, choroid, orbital vascular structures.

Ocular and General Physiology

• Tear Film Dynamics and Ocular Surface Physiology:
  • Precorneal tear film thickness is $3.4 \pm 2.6\,\mu m$. Total tear volume is 7\text{--}8\,\mu L$.\n * Layers (Inner to Outer): Glycocalyx (membrane-bound mucins from corneal and conjunctival stratified squamous cells), Mucous layer (secreted mucins from conjunctival goblet cells), Aqueous layer (60\% of tear thickness, secreted by lacrimal glands of Krause and Wolfring), Lipid layer (outermost layer, secreted by Meibomian glands).\n\n* **Aqueous Humor Dynamics and Outflow:**\n * Average IOP in healthy eyes is approximately 15\,mmHg.\n * Conventional Outflow Pathway (80\text{--}90\%$): Trabecular meshwork$\rightarrow$Schlemm's canal$\rightarrow$Collector channels$\rightarrow$Aqueous veins$\rightarrow Episcleral venous circulation.\n * Unconventional (Uveoscleral) Outflow Pathway (10\text{--}20\%$in humans): Iris root / Ciliary muscle / Uveal meshwork$\rightarrow$Suprachoroidal space$\rightarrow Sclera.\n\n* **Phototransduction and Photoreceptor Physiology:**\n * Resting membrane potential of dark-adapted rod cells is -40\,mV$("dark current" maintained by open cGMP-gated$\text{Na}^+ channels).\n * Light absorption converts 11-cis retinal to all-trans retinal, activating transducin and phosphodiesterase (PDE), lowering cGMP, closing \text{Na}^+$channels, and hyperpolarizing the photoreceptor to$-70\,mV\n * Regeneration of rhodopsin following complete dark adaptation requires approximately 30\,\text{minutes}.\n * Foveal RPE ratio: Each central foveal RPE cell interacts with an average of 23 photoreceptors.\n\n* **Pupillary Reflexes and Visual Resolution:**\n * Pupillary Light Reflex Pathway: Retinal ganglion cells \rightarrow$Optic tract$\rightarrow$Brachium of superior colliculus$\rightarrow$Olivary pretectal nucleus$\rightarrow$Bilateral Edinger-Westphal nuclei (via posterior commissure)$\rightarrow$Preganglionic parasympathetics via CN III$\rightarrow$Ciliary ganglion$\rightarrow$Postganglionic parasympathetics via short ciliary nerves$\rightarrow Iris sphincter pupillae.\n * Relative Afferent Pupillary Defect (RAPD) Magnitudes:\n * Anterior Ischemic Optic Neuropathy (AION): 0.6\text{--}2.7\,\text{log units}.\n * Dense Vitreous Hemorrhage: 0.6\text{--}1.2\,\text{log units}.\n * Central Serous Chorioretinopathy (CSCR): \approx 0.3\,\text{log units}.\n * Visual Acuity Resolution:\n * Snellen 6/6 'E' letter: Overall height subtends 5\,\text{minutes of arc}\ (5')$; stroke width and gap spacing subtend$1\,\text{minute of arc}\ (1').\n * Off-foveal drop-off: At 5^\circ$from the central fovea, visual acuity drops to$25\% of maximum foveal acuity.\n * Vernier Acuity: Detects spatial misalignment between two line segments; achieves peak functionality at age 14.\n * Visual Contrast Laws:\n * Bloch's Law: Threshold stimulus intensity is inversely proportional to duration (I \times t = C); assumes monotonic contrast increase with duration.\n * Broca-Sulzer Effect: Perceived brightness peaks at intermediate flash durations (\approx 50\text{--}100\,ms) rather than increasing monotonically.\n\n* **General Neurophysiology and Action Potentials:**\n * Action Potential Stages: Resting stage (-90\,mV$in large nerve fibers), Depolarization stage (permeability to$\text{Na}^+$increases, overshooting above$0\,mV$in large fibers), Repolarization stage ($\text{Na}^+$channels close,$\text{K}^+ channels open to re-establish resting potential).\n * Receptor Potentials: Triggered by opening ion channels via mechanical deformation, chemical application, temperature change, or electromagnetic radiation.\n\n* **Cardiovascular, Respiratory, Renal, and Endocrine Physiology:**\n * Cardiac Arrhythmias: Tachycardia = heart rate > 100\,\text{beats/min}$. 1st-degree AV block =$PR > 0.20\,s$. 2nd-degree Type I (Wenckebach) = progressive PR lengthening before a dropped QRS. 2nd-degree Type II = fixed non-conducted P waves. 3rd-degree = complete AV dissociation. Atrial fibrillation reduces ventricular pumping efficiency by$20\text{--}30\%$.
  • Respiratory Volumes (Average Adult Male):
  • Tidal Volume (TV): $500\,mL$
  • Inspiratory Reserve Volume (IRV): $3000\,mL$
  • Expiratory Reserve Volume (ERV): $1100\,mL$
  • Residual Volume (RV): $1200\,mL$
  • Pain Receptor Stimulation: Directly excited by bradykinin, serotonin, histamine, acetylcholine, potassium ions, acids, and proteolytic enzymes. Prostaglandins and substance P enhance sensitivity without direct excitation.
  • Renal Physiology: Each kidney contains $800,000\text{ to }1,000,000$ nephrons. Cortical nephrons ($70\text{--}80\%$) have short loops of Henle; Juxtamedullary nephrons ($20\text{--}30\%$) have long loops of Henle. Antidiuretic hormone (ADH) renders collecting ducts permeable to water.
  • Pituitary Secretions:
  • Anterior Pituitary (FLAT PEG): FSH, LH, ACTH, TSH, Prolactin, Endorphins, Growth Hormone.
  • Posterior Pituitary: ADH (Vasopressin), Oxytocin.

Ocular Biochemistry

• Corneal and Lens Biochemistry:

  • Corneal Stroma: Accounts for $90\%$ of total corneal thickness; $55\%$ of stromal collagen is Type I arranged orthogonally. Fibrillar collagens = Types I, III, V.
  • Lens Metabolism and Protection: Glutathione and glycine protect lens proteins against oxidative damage. NADPH produced via the hexose monophosphate (HMP) shunt regenerates reduced glutathione via glutathione reductase. Reduced glutathione depletion causes protein aggregation and cataract formation.
  • Crystallin Breakdown: Lens crystallins break down into insoluble albuminoids; oxidation of cysteine and methionine residues occurs in nuclear sclerosis. UV-B light exposure is associated with cortical and posterior subcapsular cataracts (not nuclear cataract). Aquaporin-0 (AQP0) regulates fluid transport and cell packing.

• Vitreous and Scleral Biochemistry:

  • Vitreous Gel Structure: Type II collagen is the predominant collagen ($> 75\%$). Central vitreous possesses lower concentrations of hyaluronan and collagen relative to the cortex. Glycosaminoglycans: Hyaluronan is the sole GAG in central vitreous; cortex contains chondroitin sulfate ($3.5\%$) and heparan sulfate ($0.3\%$). Opticin regulates collagen fibril thickness. Aging causes hyaluronan degradation and collagen fibril coagmentation (liquefaction and floaters).
  • Scleral Biochemistry: Major proteoglycans are proteodermatan sulfate and proteochondroitin sulfate (small leucine-rich proteoglycan family). Proteokeratan sulfate is absent from the sclera.

• Choroidal Vascular Biochemistry:

  • Ocular Blood Flow: $98\%$ of ocular blood flow passes through the uveal tract ($85\%$ through the choroid). Choroidal blood flow rate is $1400\,mL/\text{min per }100\,g\text{ tissue}$.
  • Choriocapillaris: Composed of highly fenestrated capillaries arranged in a lobular architecture.

• Tear Film Biochemistry:

  • Aqueous layer comprises $60\%$ of total tear film. Contains lysozyme (effective against Gram-negative bacteria and some fungi, but ineffective against Gram-positive organisms like Staphylococcus aureus), lactoferrin, IgA, and lipocalin.

Ocular and General Pathology

• Inflammation, Wound Healing, and Cell Death:

  • Acute Inflammation: Transendothelial migration and extravasation are followed by chemotaxis. Histamine and leukotrienes increase vascular permeability. Opsonization by complement ($\text{C3b}$) and antibodies ($\text{IgG}$) facilitates leucocyte phagocytosis.
  • Wound Healing: Corneal epithelium regenerates from limbal stem cells; scleral scar tissue derives from episcleral fibroblasts (choroidal scars derive from scleral fibroblasts). Optic nerve transection leads to axonal loss and demyelination without regeneration.
  • Cell Death Mechanics:
  • Necrosis: Always pathological, accompanied by cell swelling, membrane rupture, and secondary acute inflammation.
  • Apoptosis: Programmed active single-cell death mediated by caspase enzymatic cleavage, without secondary inflammation.

• Corneal Dystrophies and Histopathological Stains:

  • Stromal Corneal Dystrophies & Stains:
  • (Mnemonic: "Marilyn Monroe Always Gets Her Makeup in LA City")
  • Macular Dystrophy: Mucopolysaccharide accumulation $\rightarrow$ Alcian Blue stain (Autosomal Recessive).
  • Granular Dystrophy: Hyaline deposits $\rightarrow$ Masson Trichrome stain (Autosomal Dominant). Non-birefringent.
  • Lattice Dystrophy: Amyloid deposits $\rightarrow$ Congo Red stain (displays apple-green birefringence under polarized light; Autosomal Dominant).     
  • Anterior Corneal Dystrophies:
  • Reis-Bücklers Dystrophy: Superficial reticular opacities and sheet-like Bowman layer disruption (Autosomal Dominant).
  • Thiel-Behnke Dystrophy: Curly fibers identified on electron microscopy in superficial corneal nodules.
  • Cogan's Microcystic (Map-Dot-Fingerprint) Dystrophy: Intraepithelial microcysts and basement membrane duplication.
  • Meesmann's Dystrophy: Intraepithelial microcysts containing "peculiar substance".
  • Fuchs' Endothelial Dystrophy: Affects females more than males; progressive endothelial cell loss and Descemet's membrane thickening with guttata.

• Retinal and Macular Diseases:

  • Diabetic Retinopathy: Characterized by increased VEGF and decreased PEDF; basement membrane thickening; pericyte loss; microaneurysms.
  • Age-Related Macular Degeneration (AMD): RPE lipofuscin accumulation; hard and soft drusen accumulate between the RPE basement membrane and the inner collagenous layer of Bruch's membrane. Basal linear deposits lie between the RPE cell membrane and RPE basement membrane.
  • Stargardt Disease: Autosomal recessive mutation in the ABCA4 gene; RPE lipofuscin accumulation; end-stage features retina-RPE fusion and "beaten-metal" macula.
  • Best Vitelliform Dystrophy: Autosomal dominant mutation in BEST1 ($\text{VMD2}$) or PRPH2; egg-yolk (vitelliform) macular lesion; lipofuscin accumulation in RPE with photoreceptor atrophy.

• Glaucoma and Optic Nerve Pathology:

  • Primary Open-Angle Glaucoma (POAG): Vertical cup enlargement exceeds horizontal expansion; neuroretinal rim loss; mutations in MYOC (chromosome 1) and OPTN (chromosome 10).
  • Primary Angle-Closure Glaucoma (PACG): Risk factors include female sex, hypermetropia, shallow anterior chamber depth, short axial length, and aging anteroposterior lens thickening.
  • Acute Retinal Necrosis (ARN): Occurs in immunocompetent patients; caused by VZV or HSV-1/2; necrotizing retinitis, vitritis, and vasculitis.

• Ocular Oncology:

  • Uveal Melanoma: Unilateral; most common systemic metastasis is to the liver ($> 90\%$). Poorer prognosis linked to older age, larger size, ciliary body location, epithelioid cell component, closed-loop vascular pattern on PAS stain, monosomy 3, and gain of 8q. Favorable prognosis linked to young age, spindle cell type, and gain of 6p.
  • Retinoblastoma: Mutation in the RB1 gene (chromosome 13q14). Most common primary intraocular malignancy in children ($1 \text{ in } 20,000$). $40\%$ germline/heritable (typically bilateral), $60\%$ somatic/sporadic (unilateral). Equal sex distribution. Histology displays Flexner-Wintersteiner rosettes (lumen bounded by continuous membrane), Homer Wright rosettes (no central lumen), and fleurettes (photoreceptor differentiation).
  • Basal Cell Carcinoma (BCC): Accounts for $90\%$ of malignant eyelid tumors. Growth patterns: Nodular and Superficial (low recurrence risk); Infiltrative/Sclerosing and Basosquamous (high recurrence risk). Features peripheral palisading and retraction clefts. Associated with Gorlin-Goltz syndrome.
  • Sebaceous Cell Carcinoma: Masquerades as chalazion or blepharitis; contains yellow lipoidal material; exhibits Pagetoid spread; carries worse prognosis than Squamous Cell Carcinoma.

Microbiology and Immunology

• Ocular Microbiology and Pathogens:

  • Normal Ocular Flora: Staphylococcus epidermidis, Staphylococcus aureus, Cutibacterium acnes (Propionibacterium acnes). Bacillus cereus is NOT normal flora (causes post-traumatic endophthalmitis).
  • Postoperative Endophthalmitis: Staphylococcus epidermidis is the most common cause following cataract surgery.
  • Bacterial Keratitis: Pseudomonas aeruginosa is a Gram-negative bacillus, ubiquitous in fresh water, and the leading cause of bacterial keratitis globally in contact lens wearers. Virulence factors: Type III secretion system (T3SS), ExoU (cytotoxic cell lysis), ExoS/ExoT (GTPase/ADP-ribosyltransferase inhibiting phagocytosis).
  • Fungal Pathogens: Candida albicans is the most common yeast. Aspergillus, Fusarium, and Penicillium are moulds. Aspergillus hyphae produce collagenases.
  • Parasitic Infections:
  • Toxoplasma gondii: Protozoan parasite; most common cause of posterior uveitis/retinochoroiditis. Classic tetrad: Hydrocephalus, intracranial calcification, microcephaly, retinochoroiditis.
  • Toxocara canis / cati: Nematodes transmitted by dogs/cats. Causes visceral larva migrans and ocular toxocariasis.
  • Onchocerca volvulus: Filarial nematode transmitted by Simulium blackflies (River blindness). Pathology results from host reaction to dead microfilariae.
  • Viral Pathogens: Adenovirus serotypes 3, 7, 8, 19 cause Epidemic Keratoconjunctivitis (EKC); serotypes 1, 2, 3, 5, 7, 14 cause Pharyngoconjunctival Fever (PCF). Human Herpesvirus 8 (HHV-8) causes Kaposi sarcoma. Chlamydia trachomatis serovars A-C cause Trachoma; serovars D-K cause adult inclusion conjunctivitis.

• Immunology and Hypersensitivity:

  • Innate vs Acquired Immune System:
  • Innate System: Rapid mobilization, non-specific, lacks memory. Granulocytes (neutrophils [$25\%$ of total WBCs], eosinophils, basophils, mast cells) possess few mitochondria.
  • Mononuclear Phagocyte System: Monocytes ($12\text{--}20\,\mu m$, horseshoe nucleus, abundant mitochondria/lysosomes), Macrophages, Dendritic cells.
  • Acquired System: T and B lymphocytes; highly specific, diverse, exhibits memory.
  • Major Histocompatibility Complex (MHC) / HLA Associations:
  • HLA-B27: Ankylosing Spondylitis ($> 90\%$), Acute Anterior Uveitis ($50\%$), Reactive Arthritis, Psoriatic Arthritis.
  • HLA-A29: Birdshot Retinochoroidopathy ($> 95\%$).
  • HLA-B51: Behçet's Disease / Retinal Vasculitis.
  • HLA-DR4: Vogt-Koyanagi-Harada (VKH) Syndrome, Sympathetic Ophthalmia.
  • Ocular Hypersensitivity Conditions: Stevens-Johnson Syndrome (cytotoxic immune-complex reaction to drugs acting as haptens; causes severe conjunctival cicatrization). Vernal Keratoconjunctivitis (VKC) features elevated tear levels of eosinophil cationic protein (ECP).

Ocular Pharmacology

• Pharmacokinetics, Diffusion, and Topical Delivery:

  • Fick's Law of Diffusion: Rate of diffusion across a cell membrane is directly proportional to concentration gradient and diffusion coefficient, and inversely proportional to membrane thickness ($\text{Rate} \propto \frac{\Delta C \cdot A \cdot D}{d}$).
  • Pharmacokinetic Parameters:
  • Apparent Volume of Distribution ($V_d$): Theoretical fluid volume required to contain total body drug at plasma concentration.
  • Clearance ($CL$): Rate of drug elimination relative to plasma concentration ($CL = k_e \cdot V_d$). Quantitative parameter superior to half-life for assessing elimination efficiency.
  • Bioavailability ($F$): Fraction of unchanged drug reaching systemic circulation.
  • Topical Ocular Dynamics:
  • Natural tear volume: $7\text{--}8\,\mu L$. Standard drop size: $\approx 25\text{--}50\,\mu L$
  • Prolonging fornix residence time: Nasolacrimal occlusion for 5 minutes; using ointments or high-viscosity vehicles; surgically correcting ectropion. Alkaline or acidic pH extremes irritate and induce reflex lacrimation, accelerating clearance.

• Autonomic and IOP-Lowering Pharmacology:

  • Sympathomimetic and Adrenergic Agonists:
  • Phenylephrine: Direct $\alpha_1$-agonist (pupillary dilation without cycloplegia).
  • Apraclonidine: Selective $\alpha_2$-partial agonist (suppresses aqueous humor production).
  • Brimonidine: Highly selective $\alpha_2$-agonist (reduces production and enhances uveoscleral outflow).
  • Cocaine: Blocks reuptake of noradrenaline at sympathetic nerve endings.
  • Parasympathomimetics and Antimuscarinics:
  • Pilocarpine: Direct parasympathomimetic (contracts ciliary muscle, opens trabecular meshwork).
  • Cyclopentolate / Atropine / Tropicamide: Antimuscarinics (cycloplegia and mydriasis). Systemic toxicity: Dry mouth, facial flushing, tachycardia, fever, urinary retention.
  • Glaucoma Medications Summary:
  • Prostaglandin Analogues (Latanoprost, Travoprost, Bimatoprost): Increase uveoscleral outflow via matrix metalloproteinase induction.
  • $\beta$-Blockers (Timolol, Levobunolol, Carteolol): Non-selective $\beta_1/\beta_2$ blockers; reduce aqueous production by $50\%$. Betaxolol is $\beta_1$-selective (safer in mild pulmonary disease).
  • Carbonic Anhydrase Inhibitors (Acetazolamide, Dorzolamide, Brinzolamide): Inhibit ciliary carbonic anhydrase II, lowering aqueous formation. Side effects: Hypokalemia, metabolic acidosis, fatigue, paresthesias, renal calculi.

• Immunosuppressants and Biologics:

  • Corticosteroids: Bind cytosolic glucocorticoid receptors; inhibit NF-$\kappa$B and cytokine transcription. Side effects: Raised IOP, posterior subcapsular cataract, viral keratitis reactivation.
  • Ciclosporin & Tacrolimus: Calcineurin inhibitors; block IL-2 transcription in T-cells. Tacrolimus binds FKBP12.
  • Azathioprine & Mycophenolate Mofetil: Inhibitors of purine synthesis; cause bone marrow suppression.
  • Methotrexate: Inhibits dihydrofolate reductase (DHFR).
  • Biologic Monoclonal Antibodies:
  • Infliximab: Chimeric mouse-human anti-TNF-$\alpha$ monoclonal antibody.
  • Adalimumab: Fully humanized anti-TNF-$\alpha$ monoclonal antibody.
  • Rituximab: Anti-CD20 monoclonal antibody.
  • Tocilizumab: Anti-IL-6 receptor monoclonal antibody.

• Systemic Ocular Toxicity:

  • Chloroquine / Hydroxychloroquine: High affinity for RPE melanin; dose/duration dependent toxicity; causes bull's-eye maculopathy.
  • Amiodarone: Photosensitizing agent; causes cornea verticillata (vortex keratopathy) and optic neuropathy.
  • Local Anesthetics: Amides (lidocaine, bupivacaine) metabolized in liver; Esters (tetracaine, proparacaine) metabolized by plasma pseudocholinesterases. Hydrophobic aromatic ring linked to hydrophilic amine group. Addition of adrenaline lowers pH (acidic).

Genetics and Molecular Biology

• Cell Division and Chromosomal Mechanics:

  • Mitosis Stages (PMAT): Prophase (chromosomes condense), Metaphase (chromosomes align on equatorial plate), Anaphase (centromeres divide, chromatids separate), Telophase (daughter nuclei reform).
  • Meiosis Prophase I Stages (LZPDD): Leptotene (chromosomes condense), Zygotene (synapsis/bivalent formation), Pachytene (crossing over / chromosome thickening), Diplotene (chiasmata visible, bivalents separate), Diakinesis (coiling and nuclear envelope breakdown).
  • Numerical Abnormalities: Aneuploidy from non-disjunction or anaphase lag. Trisomy 13 = Patau syndrome; Trisomy 18 = Edwards syndrome; Trisomy 21 = Down syndrome; 47,XXY = Klinefelter syndrome; 45,X = Turner syndrome. Robertsonian translocation involves acrocentric chromosomes (13, 14, 15, 21, 22).

• Molecular Genetics and Central Dogma:

  • Human Haploid Genome: $3 \times 10^9$ base pairs of double-stranded DNA.
  • Genetic Code: Degenerate (multiple codons per amino acid), except Methionine (ATG) and Tryptophan (TGG).
  • Transcription & Translation: RNA polymerase binds promoter; pre-mRNA undergoes splicing (introns removed, exons joined), 5' capping, and 3' polyadenylation. Ribosomes translate mRNA from N-terminal to C-terminal using aminoacyl-tRNAs.
  • Ubiquitin-Proteasome System: Covalently tags damaged/cyclin proteins with ubiquitin for degradation by 26S proteasome; maintains cellular homeostasis. Lactacystin is a proteasome inhibitor.

• Inheritance Patterns and Population Genetics:

  • Autosomal Dominant: Vertical transmission, 50% offspring affected, variable expressivity, pleiotropy.
  • Autosomal Recessive: Horizontal transmission, 25% offspring affected, consanguinity, constant expressivity.
  • X-Linked Recessive: No male-to-male transmission; affected males linked through carrier females.
  • Mitochondrial Inheritance: Exclusive maternal transmission (sperm acrosome and mitochondria lost during fertilization). Both sexes affected.
  • Hardy-Weinberg Equilibrium Equation:     $p^2 + 2pq + q^2 = 1$     where $p$ = frequency of normal allele, $q$ = frequency of mutant allele, $p^2$ = homozygous normal, $2pq$ = heterozygous carrier, $q^2$ = homozygous affected.

• Ocular Gene Mutations and Gene Therapy:

  • Genetic Associations:
  • PAX6: Aniridia, Peter's anomaly.
  • FOXC1 / PITX2: Axenfeld-Rieger syndrome.
  • CYP1B1 / MYOC: Primary congenital / juvenile open-angle glaucoma.
  • FRMD7: Idiopathic infantile nystagmus.
  • RS1: Juvenile X-linked retinoschisis.
  • ABCA4: Stargardt disease, cone-rod dystrophy.
  • NYX / GPR179: Congenital stationary night blindness.
  • OPA1: Autosomal dominant optic atrophy.
  • Gene Therapy Vectors:
  • Adeno-associated virus (AAV): Small insert capacity ($< 4.7\,kb$), non-integrating, long-term expression, low immunogenicity.
  • Lentivirus / Retrovirus: Larger insert capacity, integrates into genome (risk of insertional mutagenesis).
  • Non-viral (Liposomes, Gene gun): Accommodates any DNA size, safe, but low transfection efficiency.

Ophthalmic Investigations and Diagnostic Techniques

• Orthoptic and Binocularity Assessments:

  • Cover Test: Detects tropias (manifest strabismus). Inward movement on covering fellow eye = Exotropia; Outward = Esotropia; Downward = Hypertropia; Upward = Hypotropia. Uncover test detects phorias (latent strabismus).
  • Prism Cover Test: Measures angle of deviation. Base of prism placed opposite direction of deviation (e.g., Base-In for Exotropia, Base-Out for Esotropia).
  • Hirschberg Test: Pen-torch reflection at $33\,cm$. Normal reflection is slightly nasal to pupil center. $1\,mm$ corneal displacement = $15\,\Delta$ ($7^\circ$ deviation). Temporal reflection = Esotropia; Nasal reflection = Exotropia.
  • Maddox Rod Test: Single red cylinder array converts white spot light into red line perpendicular to cylinders.
  • Horizontal Maddox Rod (cylinders horizontal $\rightarrow$ line vertical): Line to right of spot = Right Esophoria (uncrossed); Line to left of spot = Right Exophoria (crossed).
  • Vertical Maddox Rod (cylinders vertical $\rightarrow$ line horizontal): Line above spot = Right Hypophoria; Line below spot = Right Hyperphoria.
  • Stereoacuity Tests:
  • Titmus Test: Polaroid glasses ($4000\text{--}40\,\text{seconds of arc}$). Includes Wirt fly.
  • TNO Test: Red-green glasses ($480\text{--}60\,\text{seconds of arc}$).
  • Frisby Test: No glasses needed; uses real depth/plate thickness ($600\text{--}20\,\text{seconds of arc}$).
  • Lang Test: No glasses needed; uses intrinsic cylindrical lenticular grating.

• Corneal Topography and Confocal Microscopy:

  • Placido Disc Topography: Measures curvature of anterior corneal surface. Rings closer in steeper meridians.
  • Scheimpflug Imaging (Pentacam) & Scanning Slit (Orbscan): Evaluates both anterior and posterior corneal surfaces, corneal thickness mapping, and anterior chamber depth.
  • In Vivo Confocal Microscopy: Uses pinhole conjugate optics to image cellular corneal layers at high magnification; evaluates Acanthamoeba cysts, fungal hyphae, endothelial cells, and trabeculectomy blebs.

• Angiography (FFA and ICG):

  • Fundus Fluorescein Angiography (FFA):
  • Fluorescein sodium: $70\text{--}85\%$ protein bound to plasma albumin. Excitation: $490\,nm$ (blue); Emission: $530\,nm$ (green).
  • Transit Phases: Choroidal (pre-arterial) $\rightarrow$ Arterial $\rightarrow$ Capillary $\rightarrow$ Venous (laminar to full) $\rightarrow$ Late (elimination/retaining).
  • Hyperfluorescence mechanisms: Transmission/Window defect (RPE atrophy/macular hole), Leakage (CMO, neovascularization, papilloedema), Pooling (pedal/subretinal fluid), Staining (scar tissue).
  • Indocyanine Green Angiography (ICG):
  • ICG molecule: $98\%$ protein bound; does not leak through choriocapillaris fenestrations. Excitation: $810\,nm$; Emission: $830\,nm$ (infrared). Contraindicated in iodine / shellfish allergy and pregnancy.
  • Phases: Early ($2\text{--}60\,s$), Early mid-phase ($1\text{--}3\,min$), Late mid-phase ($3\text{--}15\,min$), Late phase ($15\text{--}30\,min$). Ideal for choroidal neovascularization, polypoidal choroidal vasculopathy (PCV), and choroidal tumors.

• Optical Coherence Tomography (OCT) and OCT-Angiography:

  • Principle: Low-coherence interferometry. Spectral-Domain OCT achieves axial resolution of 3\text{--}8\,\mu m$.\n * Anterior Segment OCT: Uses longer wavelength (1310\,nm$) for higher tissue penetration through sclera/limbus compared to posterior OCT ($840\,nm).\n * OCT-Angiography (OCTA): Non-invasive, no contrast dye; detects movement of red blood cells via split-spectrum amplitude-decorrelation angiography (SSADA). Higher resolution than FFA, faster, but prone to motion and projection artifacts.\n\n* **Ultrasonography (US) and Ultrasound Biomicroscopy (UBM):**\n * Standard Ocular US: Transducer frequency 8\text{--}10\,MHz$. Axial resolution$\approx 150\,\mu m$, transverse resolution$\approx 450\,\mu m$. A-scan measures axial length and acoustic spike reflectivity; B-scan provides 2D structural cross-section. Orbital US uses$3\text{--}5\,MHz for deeper orbital penetration.\n * Ultrasound Biomicroscopy (UBM): High-frequency transducer (35\text{--}50\,MHz$). High axial resolution ($30\,\mu m$), low depth penetration ($4\text{--}5\,mm); images anterior segment, iridocorneal angle, ciliary body, and anterior cysts/tumors.\n\n* **Electrophysiology:**\n * **Full-field ERG (ffERG):** Measures global mass retinal response.\n * Dark-adapted (scotopic): Dim flash \rightarrow$pure rod b-wave; Bright flash ($3.0\,\text{cd}\cdot\text{s/m}^2$)$\rightarrow mixed rod-cone a-wave (photoreceptors) and b-wave (bipolar cells).\n * Light-adapted (photopic): Single flash \rightarrow$cone a- and b-waves;$30\,Hz$flicker$\rightarrow isolated cone pathway response.\n * Electronegative ERG (normal a-wave, selectively reduced scotopic b-wave): Seen in CSNB, X-linked retinoschisis, CRVO/CRAO, Quinine toxicity, Melanoma-associated retinopathy (MAR), Batten disease (\text{CLN3}).\n * **Multifocal ERG (mfERG):** Topographical functional map of central retina (30^\circ$visual field) using array of hexagon stimuli. Ring 1 = central$3^\circ$; Ring 2 =$3\text{--}10^\circ. Early detection of hydroxychloroquine toxicity (Ring 2 amplitude depression).\n * **Pattern ERG (PERG):** Retinal ganglion cell response to reversing checkerboard. Components: P_{50}$(positive deflection at$50\,ms$, macular photoreceptor/bipolar driven) and$N_{95}$(negative deflection at$95\,ms$, macular ganglion cell driven). Normal$N_{95}/P_{50}$ratio$> 1.1$.
  • Electro-oculogram (EOG): Measures standing potential between positive cornea and negative retina (RPE-photoreceptor complex). Patient performs $30^\circ$ horizontal saccades during dark adaptation ($15\,min$) and light adaptation ($15\,min$). Result = Arden Index (Light Peak / Dark Trough ratio, $LP:DT$). Normal $LP:DT > 1.7$ ($170\%$). Severely abnormal in Best disease ($< 1.5$).
  • Visual Evoked Potential (VEP): Measures electrical activity of visual cortex. Pattern reversal VEP (prVEP): Waveform consists of $N_{75}$ (negative at $75\,ms$), $P_{100}$ (positive at $100\,ms$), and $N_{135}$ (negative at $135\,ms$). Misrouting of optic fibers in albinism demonstrated by trans-occipital crossed asymmetry.

Biostatistics, Clinical Trials, and Evidence-Based Medicine

• Data Types and Descriptive Statistics:

  • Data Types: Continuous (e.g., IOP in $mmHg$), Discrete (e.g., number of attacks), Ordinal (ordered categories, e.g., Likert scale: strongly agree to strongly disagree), Nominal (unordered categories, e.g., eye color), Binary/Dichotomous (two outcomes, e.g., dead/alive).
  • Measures of Central Tendency: Mean = arithmetic average; Median = middle score in ranked data; Mode = most frequent value.
  • Normal (Gaussian) Distribution: Standard deviation ($\sigma$) rules:
  • $\mu \pm 1\sigma \approx 68.3\%$ of values.
  • $\mu \pm 2\sigma \approx 95.4\%$ of values.
  • $\mu \pm 3\sigma \approx 99.7\%$ of values.

• Hypothesis Testing and Statistical Tests:

  • Null Hypothesis ($H_0$): Assumption of no difference/effect.
  • $p$-value: Probability of obtaining the observed results (or more extreme) by chance assuming $H_0$ is true. Significance level $\alpha = 0.05$ ($5\%$).
  • Type I Error ($\alpha$): Incorrectly rejecting $H_0$ (false positive).
  • Type II Error ($\beta$): Incorrectly accepting $H_0$ (false negative).
  • Statistical Power: $1 - \beta$ (conventionally targeted at $\ge 80\%$ or $0.80$).
  • Statistical Test Selection Rules:
  • Continuous Data, 2 Groups, Parametric: Paired $t$-test (paired data) or Unpaired $t$-test (unpaired data).
  • Continuous Data, 2 Groups, Non-Parametric: Wilcoxon signed-rank test (paired) or Mann-Whitney U test (unpaired).
  • Continuous Data, >2 Groups: ANOVA (parametric) or Kruskal-Wallis test (non-parametric).
  • Categorical Data: McNemar's test (paired) or Chi-squared / Fisher's exact test (unpaired).
  • Correlation: Pearson's $r$ (parametric linear correlation) or Spearman's $\rho$ (non-parametric rank correlation).

• Diagnostic Accuracy and 2x2 Contingency Calculations:

  • Contingency Table:     | | Condition Present | Condition Absent |     |---|---|---|     | Test Positive | True Positive (TP) | False Positive (FP) |     | Test Negative | False Negative (FN) | True Negative (TN) |
  • Formulas:
  • $\text{Sensitivity} = \frac{\text{TP}}{\text{TP} + \text{FN}}$ (Proportion of diseased individuals testing positive).
  • $\text{Specificity} = \frac{\text{TN}}{\text{TN} + \text{FP}}$ (Proportion of healthy individuals testing negative).
  • $\text{Positive Predictive Value (PPV)} = \frac{\text{TP}}{\text{TP} + \text{FP}}$ (Probability that a positive test indicates disease).
  • $\text{Negative Predictive Value (NPV)} = \frac{\text{TN}}{\text{TN} + \text{FN}}$ (Probability that a negative test indicates health).
  • $\text{Accuracy} = \frac{\text{TP} + \text{TN}}{\text{TP} + \text{TN} + \text{FP} + \text{FN}}$
  • $\text{Positive Likelihood Ratio}\ (+LR) = \frac{\text{Sensitivity}}{1 - \text{Specificity}}$
  • $\text{Negative Likelihood Ratio}\ (-LR) = \frac{1 - \text{Sensitivity}}{\text{Specificity}}$
  • Worked Calculations from AMD Example (TP=90, FP=20, FN=10, TN=180):
  • $\text{Sensitivity} = \frac{90}{90+10} = \frac{90}{100} = 90\%$
  • $\text{Specificity} = \frac{180}{180+20} = \frac{180}{200} = 90\%$
  • $\text{PPV} = \frac{90}{90+20} = \frac{90}{110} \approx 82\%$
  • $\text{NPV} = \frac{180}{180+10} = \frac{180}{190} \approx 95\%$

• Epidemiology, Biases, and Clinical Trials:

  • Biases:
  • Selection Bias: Failure to achieve proper randomisation during participant selection.
  • Recall Bias: Differences in accuracy/completeness of past event recollections between groups.
  • Attrition Bias: Unequal loss or withdrawal of participants from trial arms.
  • Lead-Time Bias: Earlier diagnosis falsely prolongs apparent survival time without altering disease outcome.
  • Confirmation Bias: Tendency to search for/favour information confirming prior beliefs.
  • Detection Bias: Systematic differences in outcome determination between groups.
  • Publication Bias: Tendency to publish positive/statistically significant findings over negative ones.
  • Study Reporting Guidelines:
  • CONSORT: Randomised Controlled Trials.
  • STROBE: Observational Studies (Cohort, Case-Control, Cross-Sectional).
  • STARD: Diagnostic Accuracy Studies.
  • PRISMA: Systematic Reviews and Meta-Analyses.
  • Wilson and Jungner Principles for Population Screening (WHO 1968):
  1. Condition should be an important health problem.
  2. Accepted treatment available for diagnosed patients.
  3. Facilities for diagnosis and treatment available.
  4. Recognisable latent or early symptomatic phase.
  5. Suitable, acceptable test/examination.
  6. Test acceptable to the population.
  7. Natural history of condition adequately understood.
  8. Agreed policy on whom to treat as patients.
  9. Cost of case-finding balanced with overall healthcare expenditure.
  10. Case-finding should be a continuous process, not a "once and for all" project.
  • Clinical Trial Phases:
  • Preclinical: Non-human in vitro / in vivo testing for toxicity, kinetics, and efficacy.
  • Phase 0: Subtherapeutic dosing in $\approx 10$ humans for pharmacokinetics.
  • Phase I: Dose-ranging safety testing in $\approx 20\text{--}100$ healthy human volunteers.
  • Phase II: Therapeutic dose testing in $\approx 100\text{--}300$ affected patients to assess efficacy and side effects.
  • Phase III: Large randomized controlled trials in $\approx 300\text{--}3000$ patients to prove safety, efficacy, and superiority/non-inferiority against gold standard.
  • Phase IV: Post-marketing surveillance in public to monitor long-term adverse effects.
  • Risk Reduction and Forest Plots:
  • Absolute Risk Reduction ($ARR$) = $\text{Control Event Rate} - \text{Experimental Event Rate}$.
  • Number Needed to Treat ($NNT$) = $\frac{1}{ARR}$.
  • Forest Plot elements: Dashed vertical line = overall meta-analysed summary effect; Solid vertical line = line of no effect; Diamond width = overall confidence interval; Horizontal whiskers = individual study 95% confidence intervals; Box size = individual study weight/power.